Literature DB >> 22555526

Population-based prevalence of abnormal cervical cytology findings and local risk factors in Ibadan, Nigeria: implications for cervical cancer control programs and human papilloma virus immunization.

J O Thomas1, K O Ojemakinde, I O Ajayi, A O Omigbodun, O I Fawole, O Oladepo.   

Abstract

OBJECTIVE: To investigate the prevalence of abnormal cervical cytological findings and local risk factors in Ibadan, Nigeria. STUDY
DESIGN: All women aged ≥15 years in each household in Idikan, Ibadan, were invited to participate in a population-based study. Structured questionnaires were administered to all consenting women. Conventional cervical Papanicolaou smears obtained from sexually active women were classified using the 2001 Bethesda system. The diagnoses were correlated with sociodemographic data and risk factors.
RESULTS: Of 2,870 women aged ≥15 years estimated to live in Idikan, 1,204 sexually active women consented to pelvic examination and cervical smears. Results were available for 1,104 women (mean age: 39.8 years). Mean ages at menarche, first sexual intercourse and first pregnancy were 16.1, 20.3 and 20.7 years, respectively. Cytological results were categorized into atypical squamous cells of undetermined significance and atypical glandular cells 22 (1.99%); low-grade 43 (3.89%) and high-grade squamous intraepithelial lesions (HSIL) 17 (1.54%); invasive cancer 2 (0.18%) and normal 593 (53.8%) and reactive changes 427 (38.7%). The prevalence of epithelial abnormalities is 7.6%. Significant host-related factors in those with HSIL and invasive cancer included older age (mean 56.2 years), high parity and gravidity, lack of formal education and being divorced (p < 0.05).
CONCLUSIONS: This study provides prevalence data and local risk factors for abnormal cervical cytology in a Nigerian population, which will be useful for planning future cervical cancer control programs.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22555526     DOI: 10.1159/000337444

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  5 in total

Review 1.  Mapping Evidence on the Burden of Breast, Cervical, and Prostate Cancers in Sub-Saharan Africa: A Scoping Review.

Authors:  Alfred Musekiwa; Maureen Moyo; Mohanad Mohammed; Zvifadzo Matsena-Zingoni; Halima Sumayya Twabi; Jesca Mercy Batidzirai; Geoffrey Chiyuzga Singini; Kabelo Kgarosi; Nobuhle Mchunu; Portia Nevhungoni; Patricia Silinda; Theodora Ekwomadu; Innocent Maposa
Journal:  Front Public Health       Date:  2022-06-16

2.  Recruiting population controls for case-control studies in sub-Saharan Africa: The Ghana Breast Health Study.

Authors:  Sarah J Nyante; Richard Biritwum; Jonine Figueroa; Barry Graubard; Baffour Awuah; Beatrice Wiafe Addai; Joel Yarney; Joe Nat Clegg-Lamptey; Daniel Ansong; Kofi Nyarko; Seth Wiafe; Joseph Oppong; Isaac Boakye; Michelle Brotzman; Robertson Adjei; Lucy T Afriyie; Montserrat Garcia-Closas; Louise A Brinton
Journal:  PLoS One       Date:  2019-04-16       Impact factor: 3.240

3.  Prevalence of cervical cancer and pre-cancerous lesions among unscreened Women in Kumasi, Ghana.

Authors:  Emmanuel Timmy Donkoh; Francis Agyemang-Yeboah; Richard Harry Asmah; Edwin K Wiredu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 4.  Cervical Cancer and Human Papillomavirus Vaccine Knowledge, Utilisation, Prevention Educational Interventions and Policy Response in Nigeria: A Scoping Review.

Authors:  Yetunde O John-Akinola; Chizoma M Ndikom; Mojisola M Oluwasanu; Temitayo Adebisi; Oluwaponmile Odukoya
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

5.  Is there any association between hormonal contraceptives and cervical neoplasia in a poor Nigerian setting?

Authors:  Leonard Ogbonna Ajah; Chibuike Ogwuegbu Chigbu; Benjamin Chukwuma Ozumba; Theophilus Chimezie Oguanuo; Paul Olisaemeka Ezeonu
Journal:  Onco Targets Ther       Date:  2015-07-27       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.